-
Evoke Pharma (EVOK) Misses Q2 EPS by 62c
-
Evoke Pharma receives patent extending GIMOTI exclusivity to 2038
-
Evoke Pharma gets patent approval extending GIMOTI protection to 2036
-
Evoke Pharma (EVOK) Misses Q1 EPS by 51c
-
Evoke Pharma (EVOK) Misses Q4 EPS by 49c
-
Evoke Pharma (EVOK) Appoints Greg Pyszczymuka to its Board
-
Evoke Pharma (EVOK) Misses Q3 EPS by 95c
-
Laidlaw Reiterates Buy Rating on Evoke Pharma (EVOK)
-
Evoke Pharma (EVOK) and EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users
-
Evoke Pharma (EVOK) Appoints Ben Smeal to its Board
-
Evoke Pharma (EVOK) Receives $3M in Proceeds from Existing Warrants
-
Evoke Pharma (EVOK) Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
-
Evoke Pharma (EVOK) Reports Q2 Loss of $0.93/sh
-
Evoke Pharma (EVOK) Announces 1:12 Reverse Share Split
-
Evoke Pharma (EVOK) Reports Commercial Strategy Progress for GIMOTI

